Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Optibiotix Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a distinct examiner and a distinct art unit.
PAK, JOHN D is the busiest examiner, with 1 pending office action. The distributed assignments favor application-specific analysis of scientific disclosure, prior art, and claim scope.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 1 | 52.3% | +37.8% |
| AL-AWADI, DANAH J | 1 | 54.6% | +13.2% |
| MORNHINWEG, JEFFREY P | 1 | 36.7% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18992645 | COMPOSITIONS AND USES THEREOF | PAK, JOHN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17044954 | Prebiotic Compositions And Methods Of Production Thereof | MORNHINWEG, JEFFREY P | 33d |
| 18992645 | COMPOSITIONS AND USES THEREOF | PAK, JOHN D | — |
| 18041485 | COMPOSITIONS AND METHODS OF PRODUCTION THEREOF | AL-AWADI, DANAH J | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1615 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18992645 | COMPOSITIONS AND USES THEREOF | PAK, JOHN D | 1699 | §102§103§112 | Non-Final OA | — | Pending | Jan 09, 2025 |
| 18041485 | COMPOSITIONS AND METHODS OF PRODUCTION THEREOF | AL-AWADI, DANAH J | 1615 | §112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 17044954 | Prebiotic Compositions And Methods Of Production Thereof | MORNHINWEG, JEFFREY P | 1793 | §103 | Final Rejection | 33d | Pending | Oct 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOptibiotix Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
John D Pak has the most, with 1 of Optibiotix Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
